Loading
Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia.
Eytan Stein led the first-in-human trial of the IDH2 inhibitor enasidenib, which won approval for relapsed IDH2-mutant AML, and was a lead investigator of AUGMENT-101, the trial establishing the menin inhibitor revumenib for KMT2A-rearranged and NPM1-mutant acute leukaemia. He heads the leukaemia service at MSKCC and directs early-phase leukaemia drug development.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin and the tags aml, menin.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Acute myeloid leukaemia.
Shares IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Memorial Sloan Kettering Cancer Center and the tag idh.
Shares AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin, Acute myeloid leukaemia.
Shares IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Acute myeloid leukaemia and the tag aml.
Shares AUGMENT-101, AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation, Revumenib, Menin.
Shares AUGMENT-101, Revumenib, Menin, IDH1 / IDH2.
Shares Blood, Acute myeloid leukaemia and the tag aml.